Insilico Medicine announced that first-in-human Phase 1 trial data for ISM6331 has been accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress 2026, scheduled for 23-27 October 2026, in Madrid, Spain.
The Rapid Oral session is listed as Developmental Therapeutic, abstract number 997, and is scheduled for Sunday, 25 October 2026, 08:30 to 10:00 in the Cordoba Auditorium, Hall 4.
ISM6331 is described as a novel, potent, small-molecule pan-TEAD inhibitor discovered and designed using Insilico Medicine’s generative AI platform Chemistry42, and the molecule is reported to target TEAD transcription factors that act downstream of the Hippo signaling pathway, the company claims.
The global, multicenter Phase 1 study is evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of ISM6331 in patients with malignant mesothelioma and other advanced solid tumors, according to the company.
Insilico Medicine is identified in the release as a clinical-stage, generative AI-driven drug discovery company headquartered in Cambridge, Massachusetts, and listed on the Hong Kong Stock Exchange under ticker 3696.
